The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the T cell priming capacity of dendritic cells

Andrew Platt, Ross McQueenie, Robert Benson, John Butcher, Martin Braddock, James M. Brewer, Iain B. McInnes, Paul Garside

Research output: Contribution to conferenceAbstractpeer-review

Fingerprint

Dive into the research topics of 'The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the T cell priming capacity of dendritic cells'. Together they form a unique fingerprint.

Medicine & Life Sciences